Skip to main content

Table 1 TMEM240 protein, mRNA expression and promoter hypermethylation in relation to the clinical parameters of Taiwan breast cancera

From: Hypermethylation of TMEM240 predicts poor hormone therapy response and disease progression in breast cancer

Characteristics

Allb

Protein expression

All

mRNA expressionc

All

DNA methylationd

Low n (%)

High n (%)

Low n (%)

High n (%)

Low n (%)

High n (%)

Overall

76

67 (88.2)

9 (11.8)

52

26 (50.0)

26 (50.0)

101

46 (8.9)

55

(54.5)

Tumor type

 IDC

60

52 (86.7)

8 (13.3)

52

26 (50.0)

26 (50.0)

98

43 (43.9)

55 (56.1)

 ILC

1

1 (100.0)

0 (0.0)

0

0 (0.0)

0 (0.0)

2

2 (100.0)

0 (0.0)

 Others

5

5 (100.0)

0 (0.0)

0

0 (0.0)

0 (0.0)

1

1 (100.0)

0 (0.0)

Tumor stage

 0, I and II

48

41 (85.4)

7 (14.6)

9

5 (55.6)

4 (44.4)

19

7 (36.8)

12 (63.2)

 III and IV

18

17 (94.4)

1 (5.6)

41

21 (51.2)

20 (48.8)

79

38 (48.1)

41 (51.9)

Tumor size

 T0–T1

11

10 (90.9)

1 (9.1)

40

24 (60.0)

16 (40.0)0.040

30

12 (40.0)

28 (60.0)

 T2–T4

52

46 (88.5)

6 (11.5)

9

2 (22.2)

7 (77.8)

68

33 (48.5)

35 (51.5)

Lymph node regional metastasis

 No

27

25 (92.6)

2 (7.4)

23

14 (60.9)

9 (39.1)

43

21 (48.8)

22 (51.2)

 Yes

36

31 (86.1)

5 (13.9)

25

11 (44.0)

14 (56.0)

51

24 (47.1)

27 (52.9)

Grade

 Well

4

3 (75.0)

1 (25.0)

7

3 (42.9)

4 (57.1) 7

10

5 (50.0)

5 (50.0)

 Moderate

27

22 (81.5)

5 (18.5)

17

9 (52.9)

8 (47.1)

40

17 (42.5)

23 (57.5)

 Poor

29

27 (93.1)

2 (6.9)

24

13 (54.2)

11 (45.8)

42

20 (47.6)

22 (52.4)

ER

 Negative

39

35 (89.7)

4 (10.0)

15

8 (53.3)

7 (46.7)

31

14 (45.2)

17 (54.8)

 Positive

37

32 (86.5)

5 (13.5)

27

13 (48.1)

14 (51.9)

68

30

(44.1)

38 (55.9)

PR

 Negative

42

39 (92.9)

3 (7.1)

16

9 (56.3)

7 (43.8)

40

16 (40.0)

24 (60.0)

 Positive

34

28 (82.4)

6 (17.6)

26

12 (46.2)

14 (53.8)

59

28 (47.5)

31 (52.5)

HER2

 Negative

42

51 (92.7)

4 (7.3)0.046

18

10 (55.6)

8 (44.4)

39

18 (46.2)

21 (53.8)

 Positive

21

16 (76.2)

5 (23.8)

22

20 (45.5)

3 (54.5)

59

25 (42.4)

34 (57.6)

TNBC

 Yes

23

22 (95.7)

1 (4.3)

10

5 (50.0)

5 (50.0)

15

6 (40.0)

9 (60.0)

 No

53

45 (84.9)

8 (15.1)

32

16 (50.0)

16 (50.0)

84

38 (45.2)

46 (54.8)

Ki-67

 < 14%

10

9 (90.0)

1 (10.0)

11

5 (45.5)

6 (54.5)

26

13 (50.0)

13 (50.0)

≧14%

16

11 (68.8)

5 (31.3)

23

10 (43.5)

13 (56.5)

66

27 (40.9)

39 (59.1)

p53

 Negative

26

26 (100.0)

0 (0.0)

          

 Positive

 

22 (88.0)

3 (12.0)

          
  1. aThese results were analyzed by the Pearson X2 test. P values with significance are shown as superscripts
  2. bFor some categories, the number of samples (n) was lower than the overall number analyzed because clinical data were unavailable for those samples
  3. cWhen the TMEM240 expression level in breast tumors was less than half of the mean of TMEM240 expression levels in adjacent normal breast tissues was defined as low expression
  4. dThe TMEM240 promoter methylation level in breast tumors being twofold higher than in adjacent normal breast tissues was defined as hypermethylation